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Abstract
A major goal of biomedicine is to understand the function of every gene in the human genome.1 
Loss-of-function (LoF) mutations can disrupt both copies of a given gene in humans and 
phenotypic analysis of such ‘human knockouts’ can provide insight into gene function. 
Consanguineous unions are more likely to result in offspring who carry LoF mutations in a 
homozygous state. In Pakistan, consanguinity rates are notably high.2 Here, we sequenced the 
protein-coding regions of 10,503 adult participants in the Pakistan Risk of Myocardial Infarction 
Study (PROMIS) designed to understand the determinants of cardiometabolic diseases in South 
Asians.3 We identified individuals carrying predicted LoF (pLoF) mutations in the homozygous 
state, and performed phenotypic analysis involving >200 biochemical and disease traits. We 
enumerated 49,138 rare (<1 % minor allele frequency) pLoF mutations. These pLoF mutations are 
predicted to knock out 1,317 genes in at least one participant. Homozygosity for pLoF mutations 
at PLAG27 was associated with absent enzymatic activity of soluble lipoprotein-associated 
phospholipase A2; at CYP2F1, with higher plasma interleukin-8 concentrations; at TREH, with 
lower concentrations of apoB-containing lipoprotein subfractions; at either A3GALT2 or NRG4, 
with markedly reduced plasma insulin C-peptide concentrations; and at SLC9A3R1, with 
mediators of calcium and phosphate signaling. Finally, APOC3 is a gene which retards clearance 
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of plasma triglyceride-rich lipoproteins and where heterozygous deficiency confers protection 
against coronary heart disease.4,5 In Pakistan, we now observe APOC3 homozygous pLoF 
carriers; we recalled these knockout humans and challenged with an oral fat load. Compared with 
wild-type family members, APOC3 knockouts displayed marked blunting of the usual post-
prandial rise in plasma triglycerides. Overall, these observations provide a roadmap for a ‘human 
knockout project’, a systematic effort to understand the phenotypic consequences of complete 
disruption of genes in humans.
Across all participants (Table 1), exome sequencing yielded 1,639,223 exonic and splice-site 
sequence variants in 19,026 autosomal genes that passed initial quality control metrics. Of 
these, 57,137 mutations across 14,345 autosomal genes were annotated as pLoF mutations 
(i.e., nonsense, frameshift, or canonical splice-site mutations predicted to inactivate a gene). 
To increase the probability that mutations annotated as pLoF by automated algorithms are 
bona fide, we removed nonsense and frameshift mutations occurring within the last 5% of 
the transcript and within exons flanked by non-canonical splice sites, splice site mutations at 
small (<15 bp) introns, at non-canonical splice sites, and where the purported pLoF allele is 
observed across primates. Common pLoF alleles are less likely to exert strong functional 
effects as they are less constrained by purifying selection; thus, we define pLoF mutations in 
the rest of the manuscript as variants with a minor allele frequency (MAF) of < 1% and 
passing the aforementioned bioinformatic filters. Applying these criteria, we generated a set 
of 49,138 pLoF mutations across 13,074 autosomal genes. The site-frequency spectrum for 
these pLoF mutations revealed that the majority was seen only in one or a few individuals 
(Extended Data Fig. 1).
Across all 10,503 PROMIS participants, both copies of 1,317 distinct genes were predicted 
to be inactivated due to pLoF mutations. A full listing of all 1,317 genes knocked out, the 
number of knockout participants for each gene, and the specific pLoF mutation(s) are 
provided in Supplementary Table 1. 891 (67.7 %) of the genes were knocked out only in one 
participant (Fig. 1a). Nearly 1 in 5 sequenced participants (1,843 individuals, 17.5 %) had at 
least one gene knocked out by a homozygous pLoF mutation. 1,504 of these 1,843 
individuals (81.6 %) were homozygous pLoF carriers for just one gene, but a minority of 
participants were knockouts for more than one gene and one participant had six genes with 
homozygous pLoF genotypes.
We compared the coefficient of inbreeding (F coefficient) in PROMIS participants with that 
of 15,249 individuals from outbred populations of European or African American ancestry. 
The F coefficient estimates the excess homozygosity compared with an outbred ancestor. 
PROMIS participants had a 4-fold higher median inbreeding coefficient compared to 
outbred populations (0.016 v 0.0041; P < 2 × 10−16) (Fig. 1b). Additionally, those in 
PROMIS who reported that their parents were closely related had even higher median 
inbreeding coefficients than those who did not (0.023 v 0.013; P < 2 × 10−16). The F 
inbreeding coefficient was correlated with the number of homozygous pLoF genes present in 
each individual. (Spearman r = 0.31; P = 5 × 10−231) (Fig. 1c). When restricted to 
individuals with high levels of inbreeding (F inbreeding coefficient > 6.25%, the expected 
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degree of autozygosity from a first-cousin union), 721 of 1,585 individuals (45%) were 
homozygous for at least one pLoF mutation.
We compared our results to three recent reports where homozygous pLoF genes have been 
catalogued: in Pakistanis living in Britain,6 in Icelanders,7 and in the Exome Aggregation 
Consortium (ExAC).8 In the PROMIS study, we identify a total of 734 unique genes in the 
homozygous pLoF state that were not observed in the other three studies (Extended Data 
Fig. 2). Intersection of the four sets of genes from these studies revealed only 25 common to 
all four studies.
In order to understand the phenotypic consequences of complete disruption of the 1,317 
pLoF genes identified in the PROMIS study, we applied three approaches. First, for 426 
genes where two or more participants were homozygous pLoF, we conducted an association 
screen against 201 distinct phenotypes (Supplementary Table 2). Second, in blood samples 
from each of 84 participants, we measured 1,310 protein biomarkers using a new, 
multiplexed, aptamer-based proteomics assay. Third, at a single gene, apolipoprotein C-III 
(encoded by APOC3), we recalled participants based on genotype and performed 
provocative physiologic testing.
In an association screen of knockout genes with phenotypes, the quantile-quantile plot of 
expected versus observed association results shows an excess of highly significant results 
without systematic inflation (Extended Data Fig. 3). Association results surpassed the 
Bonferroni significance threshold (P = 3 × 10−6, see Methods) for 26 gene-trait pairs 
(Supplementary Table 3). Below, we highlight seven results: PLA2G7, CYP2F1, TREH, 
A3GALT2, NRG4, SLC9A3R1, and APOC3.
Lipoprotein-associated phospholipase A2 (Lp-PLA2, encoded by PLA2G7) hydrolyzes 
phospholipids to generate lysophosphatidylcholine and oxidized nonesterified fatty acids. In 
observational epidemiologic studies, higher soluble Lp-PLA2 enzymatic activity has been 
correlated with increased risk for coronary heart disease; small molecule inhibitors of Lp-
PLA2 have been developed for the treatment of coronary heart disease.9 In PROMIS, we 
identified participants who are naturally deficient in the Lp-PLA2 enzyme. Two participants 
are homozygous for a splice-site mutation, PLA2G7 c.663+1G>A, and 106 are heterozygous 
for this same mutation. We observed a dose-dependent response relationship between 
genotype and enzymatic activity: when compared with non-carriers, c.663+1G>A 
homozygotes have markedly lower Lp-PLA2 enzymatic activity (−245 nmol/ml/min, P = 2 × 
10−7) whereas the 106 heterozygotes had an intermediate effect (−120 nmol/ml/min, P = 2 × 
10−77) (Fig. 2a–b). If Lp-PLA2 plays a causal role for coronary heart disease, one might 
expect those naturally deficient for this enzyme to have reduced risk for coronary heart 
disease. We tested the association of PLA2G7 c.663+1G>A with myocardial infarction 
across all participants and found that carriers of the pLoF allele did not have reduced risk 
(OR 0.97; 95% CI, 0.70 – 1.34; P = 0.87) (Fig. 2c).10,11 In contrast, at two positive control 
genes, we replicated prior observations (Supplementary Table 4); at LDLR, heterozygous 
pLoF mutations increased MI risk 20-fold and, at PCSK9, heterozygous pLoF mutations 
reduced risk by 78%. Of note, in two recent randomized controlled trials, pharmacologic Lp-
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PLA2 inhibition failed to reduce risk for coronary heart disease,12,13 a result that might have 
been anticipated by this genetic analysis.
Cytochrome P450 2F1 (encoded by CYP2F1) is primarily expressed in the lung and 
metabolizes pulmonary-selective toxins, such as cigarette smoke, and thus, modulates the 
expression of environment-associated pulmonary diseases.14 At CYP2F1, we identified two 
participants homozygous for a splice-site mutation, c.1295-2A>G. When compared with 
non-carriers, c.1295-2A>G homozygotes displayed higher soluble interleukin 8 
concentrations (3.7-fold increase, P = 2 × 10−6) (Extended Data Fig. 4). CYP2F1 c.
1295-2A>G heterozygosity had a more modest effect (2.4-fold increase, P = 2 × 10−4). 
Interleukin 8 induces migration of neutrophils in airways and is a mediator of acute 
pulmonary inflammation and chronic obstructive pulmonary disease (COPD).15 However, 
neither carrier reports a personal or family history of obstructive pulmonary disease; further 
studies of these participants are required to assess the roles of CYP2F1 and interleukin 8 on 
pulmonary physiology.
Trehalase (encoded by TREH) is an intestinal enzyme that splits the naturally-found 
unabsorbed disaccharide, trehalose, into two glucose molecules.16 Trehalase deficiency, an 
autosomal recessive trait, leads to abdominal pain, distention, and flatulence after trehalose 
ingestion. We identified six participants homozygous for a deletion of a splice acceptor site 
(c.90-9_106delTCTCTGCAGTGAGATTTACTGCCACG) in exon 2. Homozygotes, unlike 
heterozygotes or non-carriers, had lower concentrations of several apolipoprotein B-
containing lipoprotein subfractions (Supplementary Table 3) (Extended Data Fig. 5).
Alpha-1,3-galactosyltransferase 2 (encoded by A3GALT2) catalyzes the formation of the 
Gal-α1-3Galβ1-4GlcNAc-R (α-gal) epitope; the biological role of this enzyme in humans is 
uncertain.17 At A3GALT2, we identified two participants homozygous for a frameshift 
mutation, p.Thr106SerfsTer4. Compared with non-carriers, p.Thr106SerfsTer4 homozygotes 
both had dramatically reduced concentrations of fasting C-peptide (−97.4%; P = 6 × 10−12) 
and insulin (−92.3%; P = 1 × 10−4). Such an association was only observed in the 
homozygous state (Extended Data Fig. 6). A3galt2−/− mice and pigs have recently been 
shown to have glucose intolerance.18,19
To understand if the identification of only a single homozygote may still be informative, we 
performed a complementary analysis, focusing on those with the most extreme standard Z 
scores (|Z score| > 5) and requiring that there be evidence for association in heterozygotes as 
well (see Methods). This procedure highlighted neureglin 4 (NRG4), a member of the 
epidermal growth factor family extracellular ligands which is highly expressed in brown fat, 
particularly during adipocyte differentiation.20,21 At NRG4, we identified a single 
participant homozygous for a frameshift mutation, p.Ile75AsnfsTer23, who had nearly 
absent fasting insulin C-peptide concentrations (−99.3 %; P = 1 × 10−10). When compared 
with non-carriers, heterozygotes for NRG4 p.Ile75AsnfsTer23 (n = 8) displayed 48.3 % 
reduction in insulin C-peptide (P = 1 × 10−2). Mice deleted for Nrg4 have recently been 
shown to have glucose intolerance.21 The single NRG4 pLoF homozygote participant did 
not have diabetes nor elevated fasting glucose. Heterozygosity for a NRG4 pLoF mutation 
(n=26) was also not associated with diabetes or fasting glucose. More detailed phenotyping 
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will be required to definitively assess any relationship of NRG4 deficiency in humans with 
glucose intolerance.
To further dissect the consequences of a subset of homozygous pLoF genes, we measured 
1,310 protein biomarkers in 84 participants through a new, multiplexed, proteomic assay 
(SOMAscan). Among the 84 participants, there were nine genes with at least two pLoF 
homozygotes and we associated these genotypes across 1,310 protein biomarkers and 
observed a number of associations (Supplementary Table 5). We highlight two PROMIS 
participants who are homozygous pLoF at SLC9A3R1; these participants have increased 
circulating concentrations of several proteins involved in parathyroid hormone or osteoclast 
signaling including calcium/calmodulin-dependent protein kinase II (CAMK2) alpha, beta, 
and delta subunits, cAMP-regulated phosphoprotein 19, and signal transducer and activator 
of transcription (STAT) 1, 3, and 6 (Supplementary Table 5). SLC9A3R1 (aka NHERF1) 
encodes a Na+/H+ exchanger regulatory cofactor that interacts with and regulates the 
parathyroid hormone receptor; Nherf1−/− mice display hyperphosphaturia and disrupted 
protein kinase A-dependent cAMP-mediated phosphorylation.22 Humans carrying rare 
missense mutations in SLC9A3R1 have nephrolithiasis, osteoporosis, and 
hypophosphatemia.23
Apolipoprotein C-III (apoC-III, encoded by APOC3) is a major protein component of 
chylomicrons, very low-density lipoprotein cholesterol, and high-density lipoprotein 
cholesterol.24 We and others recently reported that APOC3 pLoF mutations in heterozygous 
form lower plasma triglycerides and reduce risk for coronary heart disease4,5,25; there is now 
substantial interest in APOC3 as a therapeutic target.26–28 In published studies, no APOC3 
pLoF homozygotes have been identified despite study of nearly 200,000 participants from 
the U.S. and Europe, raising concerns that complete APOC3 deficiency may be harmful. 
However, in this study of ~10,000 Pakistanis, we identified four participants homozygous 
for APOC3 p.Arg19Ter. When compared with non-carriers, p.Arg19Ter homozygotes 
displayed near-absent plasma apoC-III protein (−88.9 %, P = 5 × 10−23), lower plasma 
triglyceride concentrations (−59.6 %, P = 7 × 10−4), higher high-density lipoprotein (HDL) 
cholesterol (+26.9 mg/dL, P = 3 × 10−8); and similar levels of low-density lipoprotein (LDL) 
cholesterol (P = 0.14) (Fig. 3a–d).
ApoC-III functions as a brake on the clearance of dietary fat from the circulation and thus, 
the complete lack of this protein should promote handling of ingested fat. We re-contacted 
one homozygous pLoF proband, his wife, and 27 of his first-degree relatives for genotyping 
and physiologic investigation. We were surprised to find that the proband’s wife, a first 
cousin, was also a pLoF homozygote, leading to all nine children being obligate 
homozygotes (Fig. 3e). In this family, we challenged pLoF homozygotes (APOC3−/−; n = 6) 
and non-carriers (APOC3+/+; n = 7) with a 50 g/m2 oral fat load followed by serial blood 
testing for six hours. APOC3 p.Arg19Ter homozygotes had significantly lower post-prandial 
triglyceride excursions (triglycerides area under the curve 468.3 mg/dL*6 hours vs 1267.7 
mg/dL*6 hours; P = 1 × 10−4) (Fig. 3f). These data show that complete lack of apoC-III 
markedly improves clearance of plasma triglycerides after a fatty meal and are consistent 
with and extend an earlier report of diminished post-prandial lipemia in APOC3 pLoF 
heterozygotes.25
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Targeted gene disruption in model organisms followed by phenotypic analysis has been a 
fruitful approach to understand gene function29; here, we extend this concept to the human 
organism, leveraging naturally-occurring pLoF mutations, consanguinity, and biochemical 
phenotyping. These results permit several conclusions. First, power to identify human 
knockouts is improved with the study of multiple populations and particularly those with 
high degrees of consanguinity. Using the observed median inbreeding coefficient of 
sequenced participants and genotypes from the first 7,078 sequenced Pakistanis, we estimate 
that the sequencing of 200,000 Pakistanis, may result in up to 8,754 genes (95% CI, 8,669–
8,834) completely knocked out in at least one participant (Fig. 4). Second, a panel of 
phenotypes measured in a blood sample can yield hypotheses regarding phenotypic 
consequences of gene disruption as observed for PLA2G7, CYP2F1, TREH, A3GALT2, 
NRG4, SLC9A3R1, and APOC3. Finally, recall by genotype followed by provocative testing 
may provide physiologic insights. We used this approach to demonstrate that complete lack 
of apoC-III is tolerated and results in both lowered fasting triglyceride concentrations as 
well as substantially blunted post-prandial lipemia.
Several limitations deserve mention. First and most importantly, any given mutation 
annotated as pLoF may not truly lead to loss of protein function. To address this issue, in 
addition to bioinformatics filtration, we performed manual curation on all homozygous pLoF 
variants (n=1,580) (Supplementary Table 1 and Supplementary Table 6). Of note, such 
manual curation was not described in earlier reports.6,7,8 We found 56 variants with 
genotypes with a low number of supportive reads, 55 with poorly mapped reads 
(Supplementary Table 7), and an additional 66 where there were potential mechanisms of 
protein-truncation rescue (Extended Data Fig. 7) or occurred within exons or splice sites 
where conservation was low. Thus, we found the majority of pLoF calls (1403 out of 1580; 
89%) to be free of mapping or annotation error. However, for any given pLoF, experimental 
validation will be required to prove loss of gene function (e.g., targeted assays such as RT-
PCR of transcript and/or Western blot of protein to confirm its absence in the relevant 
tissue).
A second limitation is reduced statistical power for genotype-phenotype correlation if a gene 
is knocked-out in only 1 or 2 participants. However, this situation should improve with 
larger sample sizes (Extended Data Fig. 8). Finally, our analysis was limited to available 
phenotypes and in only one instance did we recall participants for deeper phenotyping; 
rather, a standardized clinical phenotyping protocol is desirable for each participant where a 
gene is observed to be knocked out.
These observations set the stage for a ‘human knockout project,’ a systematic effort to 
understand the phenotypic consequences of complete disruption of every gene in the human 
genome. Key elements for a human knockout project include: 1) identification of 
populations where homozygous genotypes may be enriched6,30; 2) deep-coverage 
sequencing of the protein-coding regions of the genome7; 3) availability of a broad array 
biochemical as well as clinical phenotypes across the population; 4) ability to re-contact 
knockout humans as well as family members; 5) a thorough clinical evaluation in each 
participant where a gene is observed to be knocked out; and 6) hypothesis-driven 
provocative phenotyping in selected participants.
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Methods
General overview of the Pakistan Risk for Myocardial Infarction Study (PROMIS)
The PROMIS study was designed to investigate determinants of cardiometabolic diseases in 
Pakistan. Since 2005, the study has enrolled close to 38,000 participants; the present 
investigation sequenced 10,503 participants selected as 4,793 cases with myocardial 
infarction and 5,710 controls free of myocardial infarction. Participants aged 30–80 years 
were enrolled from nine recruitment centers based in five major urban cities in Pakistan. 
Type 2 diabetes in the study was defined based on self-report or fasting glucose levels >125 
mg/dL or HbA1c > 6.5 % or use of glucose lowering medications. The institutional review 
board at the Center for Non-Communicable Diseases (IRB: 00007048, IORG0005843, 
FWAS00014490) approved the study and all participants gave informed consent.
Phenotype descriptions
Non-fasting blood samples (with the time since last meal recorded) were drawn and 
centrifuged within 45 minutes of venipuncture. Serum, plasma and whole blood samples 
were stored at −70°C within 45 minutes of venipuncture. All samples were transported on 
dry ice to the central laboratory at the Center for Non-Communicable Diseases (CNCD), 
Pakistan, where serum and plasma samples were aliquoted across 10 different storage vials. 
Samples were stored at −70°C for any subsequent laboratory analyses. All biochemical 
assays were conducted in automated auto-analyzers. At CNCD Pakistan, measurements for 
total-cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, and creatinine were made 
in serum samples using enzymatic assays; whereas levels of HbA1c were measured using a 
turbidemetric assay in whole-blood samples (Roche Diagnostics, USA). For further 
measurements, aliquots of serum and plasma samples were transported on dry ice to the 
Smilow Research Center, University of Pennsylvania, USA, where following biochemical 
assays were conducted: apolipoproteins (apoA-I, apoA-II, apoB, apoC-III, apoE) and non-
esterified fatty acids were measured through immunoturbidometric assays using kits by 
Roche Diagnostics or Kamiya; lipoprotein (a) levels were determined through a 
turbidimetric assay using reagents and calibrators from Denka Seiken (Niigata, Japan); 
LpPLA2 mass and activity levels were determined using immunoassays manufactured by 
diaDexus (San Francisco, CA, USA); measurements for insulin, leptin and adiponectin were 
made using radio-immunoassays by LINCO (MO, USA); levels of adhesion molecules 
(ICAM-1, VCAM-1, P- and E-Selectin) were determined through enzymatic assays by R&D 
(Minneapolis, MN, USA); and measurements for C-reactive protein, alanine transaminase, 
aspartate transaminase, cystatin-C, ferritin, ceruloplasmin, thyroid stimulating hormone, 
alkaline phosphatase, sodium, potassium, choloride, phosphate, sex-harmone binding 
globulin were made using enzymatic assays manufactured by Abbott Diagnostics (NJ, 
USA). Glomerular filtration rate (eGFR) was estimated from serum creatinine levels using 
the MDRD equation. ApoC-III levels were determined in an autoanalyzer using a 
commercially available ELISA by Sekisui Diagnostics (Lexington, USA). We also measured 
the following 52 protein biomarkers by multiplex immunoassay using a customised panel on 
the Luminex 100/200 instrument by RBM (Myriad Rules Based Medicine, Austin, TX, 
USA): fatty acid binding protein, granuloctye monocyte colony stimulating factor, 
granulocyte colony stimulating factor, interferon gamma, interleukin-1 beta, interleukin 1 
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receptor, interleukin 2, interleukin 3, interleukin 4, interleukin 5, interleukin 6, interleukin 7, 
interleukin 8, interleukin 10, interleukin 18, interleukin p40, interleukin p70, interleukin 15, 
interleukin 17, interleukin 23, macrophage inflammatory protein 1 alpha, macrophage 
inflammatory protein 1 beta, malondialdehyde-modified LDL, matrix metalloproteinase 2, 
matrix metalloproteinase 3, matrix metalloproteinase 9, nerve growth factor beta, tumor 
necrosis factor alpha, tumor necrosis factor beta, brain-derived neurotrophic factor, CD40, 
CD40 ligand, eotaxin, factor VII, insulin-like growth factor 1, lecithin-type oxidized LDL 
receptor 1, monocyte chemoattractant protein 1, myeloperoxidase, N-terminal prohormone 
of brain natriuretic peptide, neuronal cell adhesion molecule, pregnancy-associated plasma 
protein A, soluble receptor for advanced glycation end-products, sortilin, stem cell factor, 
stromal cell-derived factor 1, thrombomodulin, S100 calcium binding protein B, and 
vascular endothelial growth factor.
Laboratory methods for array-based genotyping
As previously described, a genomewide association scan was performed using the Illumina 
660 Quad array at the Wellcome Trust Sanger Institute (Hinxton, UK) and using the Illumina 
HumanOmniExpress at Cambridge Genome Services, UK.31 Initial quality control (QC) 
criteria included removal of participants or single nucleotide polymorphisms (SNPs) that 
had a missing rate >5%. SNPs with a MAF <1% and a P-value of <10−7 for the Hardy-
Weinberg equilibrium test were also excluded from the analyses. In PROMIS, further QC 
included removal of participants with discrepancy between their reported sex and genetic sex 
determined from the X chromosome. To identify sample duplications, unintentional use of 
related samples (cryptic relatedness) and sample contamination (individuals who seem to be 
related to nearly everyone in the sample), identity-by-descent (IBD) analyses were 
conducted in PLINK.32
Laboratory methods for exome sequencing
Exome sequencing—Exome sequencing was performed at the Broad Institute. 
Sequencing and exome capture methods have been previously described.33,34 A brief 
description of the methods is provided below.
Receipt/quality control of sample DNA—Samples were shipped to the Biological 
Samples Platform laboratory at the Broad Institute of MIT and Harvard (Cambridge, MA, 
USA). DNA concentration was determined by PicoGreen (Invitrogen; Carlsbad, CA, USA) 
prior to storage in 2D-barcoded 0.75 ml Matrix tubes at −20 °C in the SmaRTStore (RTS, 
Manchester, UK) automated sample handling system. Initial quality control (QC) on all 
samples involving sample quantification (PicoGreen), confirmation of high- molecular 
weight DNA and fingerprint genotyping and gender determination (Illumina iSelect; 
Illumina; San Diego, CA, USA). Samples were excluded if the total mass, concentration, 
integrity of DNA or quality of preliminary genotyping data was too low.
Library construction—Library construction was performed as previously described35, 
with the following modifications: initial genomic DNA input into shearing was reduced from 
3μg to 10–100ng in 50μL of solution. For adapter ligation, Illumina paired end adapters were 
replaced with palindromic forked adapters, purchased from Integrated DNA Technologies, 
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with unique 8 base molecular barcode sequences included in the adapter sequence to 
facilitate downstream pooling. With the exception of the palindromic forked adapters, the 
reagents used for end repair, A-base addition, adapter ligation, and library enrichment PCR 
were purchased from KAPA Biosciences (Wilmington, MA, USA) in 96-reaction kits. In 
addition, during the post-enrichment SPRI cleanup, elution volume was reduced to 20 μL to 
maximize library concentration, and a vortexing step was added to maximize the amount of 
template eluted.
In-solution hybrid selection—1,970 samples underwent in-solution hybrid selection as 
previously described35, with the following exception: prior to hybridization, two normalized 
libraries were pooled together, yielding the same total volume and concentration specified in 
the publication. 8,808 samples underwent hybridization and capture using the relevant 
components of Illumina’s Rapid Capture Exome Kit and following the manufacturer’s 
suggested protocol, with the following exceptions: first, all libraries within a library 
construction plate were pooled prior to hybridization, and second, the Midi plate from 
Illumina’s Rapid Capture Exome Kit was replaced with a skirted PCR plate to facilitate 
automation. All hybridization and capture steps were automated on the Agilent Bravo liquid 
handling system.
Preparation of libraries for cluster amplification and sequencing—Following 
post-capture enrichment, libraries were quantified using quantitative PCR (KAPA 
Biosystems) with probes specific to the ends of the adapters. This assay was automated 
using Agilent’s Bravo liquid handling platform. Based on qPCR quantification, libraries 
were normalized to 2nM and pooled by equal volume using the Hamilton Starlet. Pools were 
then denatured using 0.1 N NaOH. Finally, denatured samples were diluted into strip tubes 
using the Hamilton Starlet.
Cluster amplification and sequencing—Cluster amplification of denatured templates 
was performed according to the manufacturer’s protocol (Illumina) using HiSeq v3 cluster 
chemistry and HiSeq 2000 or 2500 flowcells. Flowcells were sequenced on HiSeq 2000 or 
2500 using v3 Sequencing-by-Synthesis chemistry, then analyzed using RTA v.1.12.4.2. 
Each pool of whole exome libraries was run on paired 76bp runs, with and 8 base index 
sequencing read was performed to read molecular indices, across the number of lanes 
needed to meet coverage for all libraries in the pool.
Read mapping and variant discovery—Samples were processed from real-time base-
calls (RTA v.1.12.4.2 software [Bustard], converted to qseq.txt files, and aligned to a human 
reference (hg19) using Burrows–Wheeler Aligner (BWA).36 Aligned reads duplicating the 
start position of another read were flagged as duplicates and not analysed. Data was 
processed using the Genome Analysis ToolKit (GATK v3).37–39 Reads were locally 
realigned around insertions-deletions (indels) and their base qualities were recalibrated. 
Variant calling was performed on both exomes and flanking 50 base pairs of intronic 
sequence across all samples using the HaplotypeCaller (HC) tool from the GATK to 
generate a gVCF. Joint genotyping was subsequently performed and ‘raw’ variant data for 
each sample was formatted (variant call format (VCF)). Single nucleotide polymorphisms 
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(SNVs) and indel sites were initially filtered after variant calibration marked sites of low 
quality that were likely false positives.
Data analysis QC—Fingerprint concordance between sequence data and fingerprint 
genotypes was evaluated. Variant calls were evaluated on both bulk and per- sample 
properties: novel and known variant counts, transition–transversion (TS–TV) ratio, 
heterozygous–homozygous non-reference ratio, and deletion/insertion ratio. Both bulk and 
sample metrics were compared to historical values for exome sequencing projects at the 
Broad Institute. No significant deviation of from historical values was noted.
Data processing and quality control of exome sequencing
Variant annotation—Variants were annotated using Variant Effect Predictor40 and the 
LOFTEE41 plugin to identify protein-truncating variants predicted to disrupt the respective 
gene’s function with “high confidence.” Each allele at polyallelic sites was separately 
annotated.
Sample level quality control—We performed quality control of samples using the 
following steps. For quality control of samples, we used bi-allelic SNVs that passed the 
GATK VQSR filter and were on genomic regions targeted by both ICE and Agilent exome 
captures. We removed samples with discordance rate > 10% between genotypes from exome 
sequencing with genotypes from array-based genotyping and samples with sex mismatch 
between inbreeding coefficient on chromosome X and fingerprinting. We tested for sample 
contamination using the verifyBamID software, which examines the proportion of non-
reference bases at reference sites, and excluded samples with high estimated contamination 
(FREEMIX scores > 0.2).42 After removing monozygotic twins or duplicate samples using 
the KING software43, we removed outlier samples with too many or too few SNVs (>17,000 
or <12,000 total variants; >400 singletons; and >300 doubletons). We removed those with 
extreme overall transition-to-transversion ratios (>3.8 or <3.3) and heterozygosity 
(heterozygote:non-reference homozygote ratio >6 or <2). Finally, we removed samples with 
high missingness (>0.05).
Variant level quality control—Variant score quality recalibration was performed 
separately for SNVs and indels use the GATK VariantRecalibrator and ApplyRecalibration 
to filter out variants with lower accuracy scores. Additionally, we removed sites with an 
excess of heterozygosity calls (InbreedingCoeff <−0.3). To further reduce the rate of 
inaccurate variant calls, we further filtered out SNVs with low average quality (quality per 
depth of coverage (QD) < 2) and a high degree of missingness (> 20 %), and indels also with 
low average quality (quality per depth of coverage (QD) < 3) and a high degree of 
missingness (> 20 %).
Laboratory methods for proteomics
Protein capture—For 91 participants, enriched for homozygous pLoF mutations, we 
measured 1,310 protein analytes in plasma using the SOMAscan assay (SomaLogic, 
Boulder, CO, USA). Protein-capture was performed using modified aptamer technology as 
previously described.44 Briefly, modified nucleotides, analogous to antibodies, on a custom 
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DNA microarray recognize intact tertiary protein structures. After washing, complexes are 
released from beads by photocleavage of the linker with UV light and the resultant relative 
fluorescent unit is proportional to target protein.
Quality control—Samples (n = 7) were excluded if they showed evidence of systematic 
inflation of association, or >5 % of traits in the top or bottom 1st percentile of the analytic 
distribution.
Methods for manual curation of a subset of pLoF variants
Manual curation was performed collaboratively by three geneticists: 25 pLoF variant calls 
were reviewed independently by two reviewers and compared to ensure similar review 
criteria before the remainder was divided and separately assessed by each of the two 
reviewers separately. A third reviewer resolved discrepancies. Read and genotype support 
was confirmed by review of reads in Integrative Genomics Viewer. We flagged pLoF 
variants for any of the following six reasons: 1) read-mapping flags; 2) genotyping flags; 3) 
presence of an additional polymorphism which rescues protein truncation; 4) presence of an 
additional polymorphism which rescues splice site; 5) if affecting a minority of transcripts; 
and 6) polymorphism occurs at exon or splice site with low conservation. Criteria for these 
reasons are provided in Supplementary Table 6.
Methods for inbreeding analyses
Array-derived runs of homozygosity—Analyses were conducted in PLINK32 using 
genome-wide association (GWAS) data in PROMIS and HapMap 3 populations. Segments 
of the genome that were at-least 1.5 Mb long, had a SNP density of 1 SNP per 20 kb and had 
25 consecutive homozygous SNPs (1 heterozygous and/or 5 missing SNPs were permitted 
within a segment) were defined to be in a homozygous state (or referred as “runs of 
homozygosity” (ROH)), as described previously.45 Homozygosity was expressed as the 
percentage of the autosomal genome found in a homozygous state, and was calculated by 
dividing the sum of ROH length within each individual by the total length of the autosome in 
PROMIS and HapMap 3 populations respectively. To investigate variability in homozygosity 
explained by parental consanguinity, the difference in R2 is reported for a linear regression 
model of homozygosity including and excluding parental consanguinity on top of age, sex 
and the first 10 principal components derived from the typed autosomal GWAS data.
In PROMIS, 39.0% of participants reported that their parents were cousins and 39.8% 
reported themselves being married to a cousin. An expectation from consanguinity is long 
regions of autozygosity, defined as homozygous loci identical by descent.46 Using genome-
wide genotyping data available in 18,541 PROMIS participants, we quantified the length of 
runs of homozygosity, defined as homozygous segments at least 1.5 megabases long. We 
compared the lengths of runs of homozygosity among PROMIS participants with those seen 
in other populations from the International HapMap3 Project. Median length of genome-
wide homozygosity among PROMIS participants was 6–7 times higher than participants of 
European (CEU, TSI) (P = 3.6 × 10−37), East Asian (CHB, JPT, CHD) (P = 5.4 × 10−48) and 
African ancestries (YRI, MKK) (P = 1.3 × 10−40), respectively (Extended Data Fig. 9).
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Sequencing-derived coefficient of inbreeding—We compared the coefficient of 
inbreeding distributions of 10,503 exome sequenced PROMIS participants with 15,248 
participants (European ancestry = 12,849, and African ancestry = 2,399) who were exome 
sequenced at the Broad Institute (Cambridge, MA) from the Myocardial Infarction Genetics 
consortium.34 We extracted approximately 5,000 high-quality polymorphic SNVs in linkage 
equilibrium present on both target intervals that passed variant quality control metrics based 
on HapMap 3 data.47 Using PLINK, we estimated the coefficient of inbreeding separately 
within each ethnicity group.32 The coefficient of inbreeding was estimated as the observed 
degree of homozygosity compared with the anticipated homozygosity derived from an 
estimated common ancestor.48 The Wilcoxon-Mann-Whitney test was used to test whether 
PROMIS participants had different median coefficients of inbreeding compared to other 
similarly sequenced outbred individuals and whether the median coefficient of inbreeding 
was different between PROMIS participants who reported parental relatedness versus not. A 
two-sided P of 0.05 was the pre-specified threshold for statistical significance.
Methods for sequencing projection analysis
To compare the burden of unique completely inactivated genes in the PROMIS cohort with 
outbred cohorts of diverse ethnicities, we extracted the minor allele frequencies (maf) of 
“high confidence” loss-of-function mutations observed in the first 7,078 sequenced PROMIS 
participants, and in European, African, and East Asian ancestry participants from the Exome 
Aggregation Consortium (ExAC r0.3; exac.broadinstitute.org). For each gene and for each 
ethnicity, the combined minor allele frequency (cmaf) of rare (maf < 0.1%) “high 
confidence” loss-of-function mutations was calculated. We then simulated the number of 
unique completely inactivated genes across a range of sample sizes per ethnicity and 
PROMIS. The expected probability of observing complete inactivation (two pLoF copies in 
an individual) of a gene was calculated as , which accounts for 
allozygous and autozygous, respectively, mechanisms for complete genie knockout. F, the 
inbreeding coefficient, is defined as 
. For PROMIS, the 
median F inbreeding coefficient (0.016) was used for estimation. Down-sampling within the 
observed sample size for both high-confidence pLoF mutations and synonymous variants did 
not deviate significantly from the expected trajectory (Extended Data Fig. 10). For a range of 
sample sizes (0–200,000), each gene was randomly sampled under a binomial distribution 
( ) and it was determined if the gene was successfully sampled at least 
once. To refine the estimated count of unique genes per sample size, each sampling was 
replicated ten times.
Methods for constraint score analysis
We sought to determine whether the observed homozygous pLoF genes were under less 
evolutionary constraint by first obtaining constraint loss of function constraint scores derived 
from the Exome Aggregation Consortium (Lek M et al, in preparation).49,50 Briefly, we used 
the number of observed and expected rare (MAF < 0.1%) loss of function variants per gene 
to determine to which of three classes it was likely to belong: pLoF (observed variation 
matches expectation), recessive (observed variation is ~50% expectation), or 
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haploinsufficient (observed variation is <10% of expectation). The probability of being loss 
of function intolerant (pLI) of each transcript was defined as the probability of that transcript 
falling into the haploinsufficient category. Transcripts with a pLI ≥ 0.9 are considered very 
likely to be loss of function intolerant; those with pLI ≤ 0.1 are not likely to be loss of 
function intolerant. A list of 1,317 genes were randomly sampled from a list of sequenced 
genes 1,000 times and the proportion of loss of function intolerant genes compared to the 
proportion of the observed homozygous pLoF genes was compared using the chi square test. 
The likelihood that the distribution of the test statistics deviated from the pLoF was 
ascertained.
Additionally, we sought to determine whether there were genes with appreciable pLoF allele 
frequencies yet relative depletion of homozygous pLoF genotypes. We computed estimated 
genotype frequencies based on Hardy-Weinberg equilibrium and the F inbreeding coefficient 
and compared the frequencies to the observed genotype counts with the chi square 
goodness-of-fit test. A nominal P < 0.05 is used to demonstrate at least nominal association.
The observed 1,317 homozygous pLoF genes were less likely to be classified as highly 
constrained (odds ratio 0.14; 95% CI 0.12, 0.16; P < 1 × 10−10). Additionally, the 1,317 
homozygous pLoF genes are substantially depleted of genes described to be essential for 
survival and proliferation in four human cancer cell lines (12 of 870 essential genes 
observed, 1.4%).51
A number of genes previously predicted to be required for viability in humans were 
observed in the homozygous pLoF state in humans (Supplementary Table 8). For example, 
40 of the 1,317 genes have been associated with embryonic or perinatal lethality as 
homozygous pLoF in mice.52 Furthermore, 56 genes predicted to be essential using mouse/
human conservation data53 are tolerated as homozygous pLoF in Pakistani adults. In fact, 9 
genes are in both datasets and are also modeled as LoF intolerant.50 One such gene, EP400 
(also known as p400), influences cell cycle regulation via chromatin remodeling54 and is 
critical for maintaining the identity of murine embryonic stem cells55 but we observe an 
adult human homozygous for disruption of a canonical splice site (intron 3 of 52; c.
1435+1G>A) in EP400. Conversely, we observed 90 genes where the heterozygous pLoF 
genotype is of appreciable frequency but the homozygous pLoF genotype is depleted (at P 
value threshold < 0.05) (Supplementary Table 9).
Methods for rare variant association analysis
Recessive model association discovery—We sought to determine whether complete 
loss-of-function of a gene was associated with a dense array of phenotypes. We extracted a 
list of individuals per gene who were homozygous for a high confidence pLoF allele that 
was rare (minor allele frequency < 1 %) in the cohort. From a list of 1,317 genes where there 
was at least one participant homozygous pLoF and a list of 201 traits, we initially considered 
264,717 gene-trait pairings. To reduce the likelihood of false positives, we only considered 
gene-trait pairs where there were at least two homozygous pLoF alleles per gene phenotyped 
for a given trait yielding 18,959 gene-trait pairs for analysis. For all analyses, we constructed 
generalized linear models to test whether complete loss of function versus non-carriers was 
associated with trait variation. A logit link was used for binomial outcomes. Right-skewed 
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continuous traits were natural log transformed. Age, sex, and myocardial infarction status 
were used as covariates in all analyses. We extracted principal components of ancestry using 
EIGENSTRAT to control for population stratification in all analyses.56 For lipoprotein-
related traits, the use of lipid-lowering therapy was used as a covariate. For glycemic 
biomarkers, only non-diabetics were used in the analysis. The P threshold for statistical 
significance was 0.05/18,959 = 3 × 10−6.
Heterozygote association replication—We hypothesized that some of the associations 
for homozygous pLoF alleles will display a more modest effect for heterozygous pLoF 
alleles. Thus, the aforementioned analyses were performed comparing heterozygous pLoF 
carriers to non-carriers for the 26 homozygous pLoF-trait associations that surpassed 
prespecified statistical significance. A P of 0.05/26 = 0.002 was set for statistical 
significance for these restricted analyses.
Association for single genic homozygotes—We performed an exploratory analysis 
of gene-trait pairs where there was only one phenotyped homozygous pLoF. We performed 
the above association analyses for genes where there was only one homozygous pLoF 
phenotyped for a given trait and we focused on those with the most extreme standard Z score 
statistics (|Z score| > 5) from the primary association analysis and required that there to also 
be nominal evidence for association (P < 0.05) in heterozygotes as well to maximize 
confidence in an observed single homozygous pLoF-trait association.
Recessive model association discovery for proteomics—Among the 84 
participants with proteomic analyses of 1,310 protein analytes, 9 genes were observed in the 
homozygous pLoF state at least twice. We log transformed each analyte and associated with 
homozygous pLoF genotype status, adjusting for proteomic plate, age, sex, myocardial 
infarction status, and principal components. Gene-analyte associations were considered 
significant if P values were less than 0.05/(1,310 × 9) = 4.3 × 10−6.
Methods for recruitment and phenotyping of an APOC3 p.Arg19Ter proband and relatives
Methods for Sanger sequencing—We collected blood samples from a total of 28 
subjects, including one of the four APOC3 p.Arg19Ter homozygous participants along with 
27 of his family and community members for DNA extraction and separated into plasma for 
lipid and apolipoprotein measurements. All subjects were consented prior to initiation of the 
studies (IRB: 00007048 at the Center for Non-Communicable Diseases, Paksitan). DNA was 
isolated from whole blood using a reference phenol-chloroform protocol.57 Genotypes for 
the p.Arg19Ter variant were determined in all 28 participants by Sanger sequencing. A 685 
bp region of the APOC3 gene including the base position for this variant was amplified by 
PCR (Expand HF PCR Kit, Roche) using the following primer sequences: Forward primer 
CTCCTTCTGGCAGACCCAGCTAAGG, Reverse primer 
CCTAGGACTGCTCCGGGGAGAAAG. PCR products were purified with Exo-SAP-IT 
(Affymetrix) and sequenced via Sanger sequencing using the same primers.
Oral fat tolerance test—Six non-carriers and seven homozygotes also participated in an 
oral fat tolerance test. Participants fasted overnight and then blood was drawn for 
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measurement of baseline fasted lipids. Following this, participants were administered an oral 
load of heavy cream (50 g fat per square meter of body surface area as calculated by the 
method of Mosteller58). Participants consumed this oral load within a time span of 20 
minutes and afterwards consumed 200 mL of water. Blood was drawn at 2, 4, and 6 hours 
after oral fat consumption as done previously.59 All lipid and apolipoprotein measurements 
from these plasma samples were determined by immunoturbidimetric assays on an ACE 
Axcel Chemistry analyzer (Alfa Wasserman). A comparisons of area-under-the curve 
triglycerides was performed between APOC3 p.Arg19Ter homozygotes and non-carriers 
using a two independent sample Student’s t test; P < 0.05 was considered statistically 
significant.
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Extended Data
Extended Data Fig. 1. pLoF mutations are typically seen in very few individuals
The site-frequency spectrum of synonymous, missense, and high-confidence pLoF mutations 
is represented. Points represent the proportion of variants within a 1 × 10−4 minor allele 
frequency bin for each variant category. Lines represent the cumulative proportions of 
variants categories. The bottom inset highlights that most pLoF variants are often seen in no 
more than one or two individuals. The top inset highlights that virtually all pLoF mutations 
are very rare.
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Extended Data Fig. 2. Intersection of homozygous pLoF genes between PROMIS and other 
cohorts
We compared the counts and overlap of unique homozygous pLoF genes in PROMIS with 
other exome sequenced cohorts.
Saleheen et al. Page 18
Nature. Author manuscript; available in PMC 2017 October 12.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Extended Data Fig. 3. QQ-plot of recessive model pLoF association analysis across phenotypes
Analyses to determine whether homozygous pLoF carrier status was associated with traits 
was performed where there were at least two homozygous pLoF carriers phenotyped per 
trait. The observed versus the expected results from 15,263 associations are displayed here 
demonstrating an excess of associations beyond a Bonferroni threshold.
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Extended Data Fig. 4. Carriers of pLoF alleles in CYP2F1 have increased interleukin-8 
concentrations
Participants who had pLoF mutations in the CYP2F1 gene had higher concentrations of 
interleukin-8 while heterozygotes had a more modest effect when compared to the rest of the 
cohort of non-carriers. Interleukin 8 concentration is natural log transformed.
Saleheen et al. Page 20
Nature. Author manuscript; available in PMC 2017 October 12.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Extended Data Fig. 5. Carriers of pLoF alleles in TREH have decreased concentrations of several 
lipoprotein subfractions
Participants who had pLoF mutations in the TREH gene had lower concentrations of several 
lipoprotein subfractions.
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Extended Data Fig. 6. Nondiabetic homozygous pLoF carriers for A3GALT2 have diminished 
insulin C-peptide concentrations
Among nondiabetics, those who were homozygous pLoF for A3GALT2 had substantially 
lower fasting insulin C-peptide concentrations. This observation was not evident in 
nondiabetic heterozygous pLoF A3GALT2 participants. Insulin C-peptide is natural log 
transformed.
Saleheen et al. Page 22
Nature. Author manuscript; available in PMC 2017 October 12.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Extended Data Fig. 7. Example of a second polymorphism in-phase which rescues a putative 
protein-truncating mutation
Short-reads aligning to genomic positions 65,339,112 to 65,339,132 on chromosome 1 are 
displayed for one individual with a putative homozygous pLoF genotype in this region. The 
single nucleotide polymorphism at position 65,339,122 from G to T is annotated as a 
nonsense mutation in the JAK1 gene. However, all three homozygotes of this mutation 
carried a tandem single nucleotide polymorphism in the same codon (A to G at 65,339,124) 
thus resulting in a glutamine and effectively rescuing the protein-truncating mutation.
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Extended Data Fig. 8. Anticipated number of genes knocked out with increasing sample sizes by 
minimum knockout count
We simulate the number of genes expected to be knocked out by minimum knockout count 
per gene at increasing sample sizes. We perform this simulation with and without the 
observed inbreeding.
Extended Data Fig. 9. PROMIS participants have an excess burden of runs of homozygosity 
compared with other populations
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Consanguinity leads to regions of genomic segments that are identical by descent and can be 
observed as runs of homozygosity. Using genome-wide array data in 17,744 PROMIS 
participants and reference samples from the International HapMap 3, the burden of runs of 
homozygosity (minimum 1.5 Mb) per individual was derived and population-specific 
distributions are displayed, with outliers removed. This highlights the higher median runs of 
homozygosity burden in PROMIS and the higher proportion of individuals with very high 
burdens.
Extended Data Fig. 10. Down-sampling of synonymous and high confidence pLoF variants to 
validate simulation
We ran simulations to estimate the number of unique, completely knocked out genes at 
increasing sample sizes. Prior to applying our model, we first applied this approach to a 
range of sample sizes below 7,078 for variants that were not under constraint, synonymous 
variants (a.), and for high-confidence null variants (b.). At the observed sample size, we did 
not appreciate significant selection. We expect that at increasing sample sizes, there may be 
a subset of genes that will not be tolerated in a homozygous pLoF state. In fact, our 
estimates are slightly more conservative when comparing outbred simulations with a recent 
description of >100,000 Icelanders using a more liberal definition for pLoF mutations.
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Fig 1. Homozygous pLoF burden in PROMIS is driven by excess autozygosity
a, Most genes are observed in the homozygous pLoF state in only single individuals. b. The 
distribution of F inbreeding coefficient of PROMIS participants is compared to those of 
outbred samples of African (AFR) and European (EUR) ancestry. c, The burden of 
homozygous pLoF genes per individual is correlated with coefficient of inbreeding.
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Fig 2. Carriers of PLA2G7 splice mutation have diminished Lp-PLA2 mass and activity but 
similar risk for coronary heart disease risk when compared to non-carriers
a.–b. Carriage of a splice-site mutation, c.663+1G>A, in PLA2G7 leads to a dose-dependent 
reduction of both lipoprotein-associated phospholipase A2 (Lp-PLA2) mass (P = 6 × 10−5) 
and activity (P = 2 × 10−7), with homozygotes having no circulating Lp-PLA2. c. Despite 
substantial reductions of Lp-PLA2 activity, PLA2G7 c.663+1G>A heterozygotes and 
homozygotes have similar coronary heart disease risk when compared with non-carriers (P = 
0.87).
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Fig 3. APOC3 pLoF homozygotes have diminished fasting triglycerides and blunted post-
prandial lipemia
a.–d. APOC3 pLoF genotype status, apolipoprotein C-III, triglycerides, HDL cholesterol 
and LDL cholesterol distributions among all sequenced participants. Apolipoprotein C-III 
concentration is displayed on a logarithmic base 10 scale. e. A proband with APOC3 pLoF 
homozygote genotype as well as several family members were recalled for provocative 
phenotyping. Surprisingly, the spouse of the proband was also a pLoF homozygote, leading 
to nine obligate homozygote children. Given the extensive number of first-degree unions, the 
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pedigree is simplified for clarity. f. APOC3 p.Arg19Ter homozygotes and non-carriers 
within the same family were challenged with a 50 g/m2 fat feeding. Homozygotes had lower 
baseline triglyceride concentrations and displayed marked blunting of post-prandial rise in 
plasma triglycerides.
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Fig 4. Simulations anticipate many more homozygous pLoF genes in the PROMIS cohort
Number of unique homozygous pLoF genes anticipated with increasing sample sizes 
sequenced in PROMIS compared with similar African (AFR) and European (EUR) sample 
sizes. Estimates derived using observed allele frequencies and degree of inbreeding.
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Table 1
Baseline characteristics of exome sequenced study participants.
Characteristic Value (n = 10,503)
Age (yrs) – mean (sd) 52.0 (9.0)
Women – no. (%) 1,802 (17.2 %)
Parents closely related – no. (%) 4,101 (39.0 %)
Spouse closely related – no. (%) 4,182 (39.8 %)
Ethnicity – no. (%)
 Urdu 3,846 (36.6 %)
 Punjabi 3,668 (34.9 %)
 Sindhi 1,128 (10.7 %)
 Pathan 589 (5.6 %)
 Memon 141 (1.3 %)
 Gujarati 109 (1.0 %)
 Balochi 123 (1.2 %)
 Other 891 (8.5 %)
Hypertension – no. (%)* 4,744 (45.2 %)
Hypercholesterolemia – no. (%)† 2,924 (27.8 %)
Diabetes mellitus – no. (%)‡ 4,264 (40.6 %)
Coronary heart disease – no. (%)§ 4,793 (45.6 %)
Smoking – no. (%)‖ 4,201 (40.0 %)
BMI (m/kg2) – mean (sd) 25.9 (4.2)
*
Hypertension defined as systolic blood pressure ≥140 mmHg, diastolic blood pressure ≥90 mmHg, or antihypertensive treatment.
†
Hypercholesterolemia defined as serum total cholesterol >240 mg/dL, lipid lowering therapy or self-report.
‡
Diabetes defined as fasting blood glucose ≥126 mg/dL, or HbA1c >6.5 %, oral hypoglycemics, insulin treatment, or self-report.
§Coronary heart disease defined as acute myocardial infarction as determined by clinical symptoms with typical EKG findings or elevated serum 
troponin I.
‖Smoking defined as active current or prior tobacco smoking.
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